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Background: Antidepressant efficacy of omega-3 polyunsaturated fatty acid (n-3 PUFA) treatment in
coronary artery disease (CAD) patients remains unpredictable. N-3 PUFA can mitigate oxidative stress,
which is common in CAD and may contribute to depressive symptoms. This study investigated whether
greater pre-treatment oxidative stress, measured by the ratios of late-stage lipid peroxidation markers
(malondialdehyde [MDA], 4-hydroxy-2-nonenal [4-HNE], and 8-isoprostane [8-ISO]) to an early-stage
marker (lipid hydroperoxides [LPH]), predicted n-3 PUFA antidepressant benefits in CAD.
Methods: This was a secondary analysis of CAROTID (CAD Randomized Omega-3 Trial in Depression,
NCT00981383). Patient demographics and medical characteristics were collected. Depressive symptoms
were measured using the 17-item Hamilton Depression Rating Scale (HAM-D). Patients were then ran-
domized to receive either 1.9 g/day n-3 PUFA or placebo for 12 weeks, after which HAM-D scores were
reassessed. Baseline LPH, 4-HNE, 8-ISO, MDA and n-3 PUFA concentrations were analysed from fasting
blood.
Results: Seventy-nine patients (age = 61.1 ± 8.5, 76% male, HAM-D = 7.5 ± 6.1) were included (n = 45
placebo, n = 34 n-3 PUFA). In the n-3 PUFA group, higher baseline ratios of MDA/LPH (primary analysis:
F1,33 = 6.20, beta = 0.35, p = 0.018), 4-HNE/LPH (exploratory analysis: F1,33 = 5.35, beta = 0.32, p =
0.027), and 8-ISO/LPH (exploratory analysis: F1,33 = 6.10, beta = 0.33, p = 0.019), indicating higher oxida-
tive stress, were associated with greater depressive symptom improvement. In each model, higher base-
line EPA + DHA concentrations independently predicted depressive symptom improvement with n-3
PUFA (MDA/LPH: F1,33 = 11.05, p = 0.002; 4-HNE/LPH: F1,33 = 11.36, p = 0.002; 8-ISO/LPH: F1,33 = 13.15,
p = 0.001). No associations were observed in the placebo group.
Conclusions: n-3 PUFA may be more likely to improve depressive symptoms in CAD patients with
pre-treatment evidence of oxidative stress.
 2016 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction involvement of oxidative stress in that condition (Negi andIncreased lipid peroxidation has been associated with the pres-
ence and severity of depressive symptoms (Mazereeuw et al.,
2015). This may be particularly relevant to depressive symptoms
among patients with coronary artery disease (CAD) given theAnand, 2010).
In the early stage of lipid peroxidation, reactive oxygen species
damage unsaturated lipids, producing lipid hydroperoxides (LPH).
LPH may be neutralized by antioxidant defenses, or they may pro-
gress to later stages of lipid peroxidation if antioxidant defenses
are overwhelmed (Forman et al., 2014). Late-stage lipid peroxida-
tion markers include malondialdehyde (MDA), 4-hydroxy-2-
nonenal (4-HNE), and 8-isoprostane (8-ISO), each of which has
been previously associated with the presence of depressive symp-
toms (Mazereeuw et al., 2015).
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depressive symptoms in patients with deficits in omega-3 polyun-
saturated fatty acids (n-3 PUFA) such as eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) (Bigornia et al., 2016).
Accordingly, n-3 PUFA have shown antioxidant effects against
reactive oxygen species in clinical samples (Azizi-Soleiman et al.,
2013; Lee et al., 2013), and these effects have been associated with
reduced depressive-symptom like behaviour in animals (de Mello
et al., 2014). As such, n-3 PUFA treatment of depressive symptoms
may be particularly beneficial in patients with greater baseline evi-
dence of oxidative stress; however, this has yet to be studied.
This study investigated whether the baseline severity of oxida-
tive stress, as measured by the ratios of late-stage lipid peroxida-
tion markers (MDA, 4-HNE, and 8-ISO) to an early-stage marker
(LPH), was associated with improvement in depressive symptoms
among n-3 PUFA treated CAD patients.2. Methods
This was a secondary analysis of data from the CAD Randomized
Omega-3 Trial in Depression (CAROTID), which was a randomized,
double-blind, placebo-controlled trial investigating the antidepres-
sant efficacy of 1.9 g/day n-3 PUFA treatment compared to placebo
using a 12-week parallel arm design (Mazereeuw et al., 2016). This
study was approved by the Research Ethics Boards of Sunnybrook
Health Sciences Centre, University Health Network, and Trillium
Health Partners, and was conducted according to the principles
expressed in the Declaration of Helsinki.
2.1. Patients
Trial inclusion and exclusion criteria are detailed elsewhere
(Mazereeuw et al., 2016). Briefly, patients enrolled in CAROTID
were those with evidence of stable CAD (history of myocardial
infarction, coronary artery bypass graft, percutaneous transluminal
coronary angioplasty, or at least a 50% stenosis in one or more
major coronary artery), aged 45–80 years, male or female, and
the ability to speak and understand English. Excluded patients
were those with a significant acute medical illness, clinically signif-
icant cognitive impairment, a neurological condition, unstable ang-
ina, or a contraindication to n-3 PUFA supplements. Antidepressant
use was permitted if used at a stable dose for at least 3 months
prior to the trial.
2.2. Design
Eligible patients consenting to participate in CAROTID were
invited to a baseline visit, prior to treatment arm randomization.
At baseline, patient demographic, anthropomorphic, medical, and
medication information was documented. Whether or not a
patient had previously experienced a depressive episode was also
recorded.
Depressive symptoms were assessed using the 17-item Hamil-
ton Depression Rating Scale (HAM-D) (Williams, 1988). Fasting
(12 h overnight) blood was drawn and processed for analysis of
serum lipid peroxidation markers and plasma n-3 PUFA. Patients
were then randomized (1:1) to receive either 1.9 g/d n-3 PUFA sup-
plements (1.2 g/d EPA + 0.6 g/d DHA + 0.1 g/d other n-3 PUFA) or
placebo for 12 weeks. Depressive symptom severity was reas-
sessed using the HAM-D at week 12.
2.3. Analysis of lipid peroxidation markers and n-3 PUFA
Serum concentrations of LPH were measured based on absor-
bance relative to hydroperoxide at 500 nm in spectrophotometry(Cayman; Item No. 705003). Serum concentrations of MDA (Cay-
man; item No. 700870) were measured based on the absorbance
of reaction products with thiobarbituric acid reactive substances
at 530 nm in spectrophotometry. Serum concentrations of 4-HNE
(Cell Biolabs, Inc.; STA-338) and 8-ISO (Cayman; item No.
516351) were quantified by standard sandwich ELISA according
to manufacturer’s instructions.
Plasma EPA and DHA concentrations were measured by gas
chromatography as previously described (Merino et al., 2011).
The sum of baseline EPA and DHA concentrations (EPA + DHA, as
a measure of plasma ‘‘omega-3 index” (Harris and Von Schacky,
2004)) were included as a planned covariate. All analyses were per-
formed blinded to treatment allocation and patient characteristics.2.4. Statistical analyses
Late-stage/early-stage ratios were calculated by dividing the
concentrations of each of MDA, 4-HNE, and 8-ISO by the concentra-
tion of LPH, yielding the MDA/LPH, 4-HNE/LPH, and 8-ISO/LPH
ratios. The MDA/LPH ratio was investigated in the primary analysis
as MDA has been the most consistently measured marker in previ-
ous depression studies (Mazereeuw et al., 2015). The HNE/LPH and
8-ISO/LPH ratios were investigated in the exploratory analysis. The
ratios were log-transformed to ensure consistent normality
between them, and the resulting transformed values were used
for analyses. Ratios of oxidative stress markers, including those
comparing late-stage to early-stage lipid peroxidation, have been
previously used to indicate the severity of oxidative stress (Scola
et al., 2016; Andreazza et al., 2007).
The baseline MDA/LPH, 4-HNE/LPH, and 8-ISO/LPH ratios were
assessed as predictors of depressive symptom change in both the
n-3 PUFA and placebo groups using a repeated measures general
linear model with HAM-D total score as the dependent variable
with 2 observations (baseline and week 12). Predictive associations
between those ratios and changes in depressive symptom scores
over 12 weeks were also investigated using linear regression to
provide context for the direction and increment of the association.
Missing data were imputed using multiple imputation (Rubin,
1987). Planned covariates were age as well as baseline plasma con-
centrations of EPA + DHA due to their previously identified rela-
tionships with depressive symptom changes in CAD patients
treated with n-3 PUFA (Carney et al., 2016) (Mazereeuw et al.,
2016). Post-hoc analyses included exploration of the associations
between each baseline ratio and depressive symptom changes
with n-3 PUFA in a subgroup that completed the study protocol
and a subgroup not using antidepressant maintenance medication.
The presence of statistical outliers was determined using the
interquartile range method and through visual inspection. Finally,
the baseline ratios were deconstructed, and associations between
individual lipid peroxidation markers and depressive symptom
changes with n-3 PUFA were explored.
Statistical models were computed using SPSS statistical
software, version 13.0, Chicago, IL, USA and all analyses were
two-tailed.3. Results
Between August 2010 and February 2014, 645 patients were
assessed for CAROTID trial eligibility and 92 patients were enrolled
into the randomization phase. As reported previously, compliance
with n-3 PUFA supplements was good; however, n-3 PUFA treat-
ment did not improve depressive symptoms over 12 weeks com-
pared to placebo (Mazereeuw et al., 2016). Of the 92 patients
enrolled in CAROTID, 79 patients (34 receiving n-3 PUFA and 45
Table 1
Baseline patient characteristics.
Characteristic Patients (n = 79) n-3 PUFA (n = 34) Placebo (n = 45) Significance
F/v2 df P
Demographics
Mean age (SD) 61.1 (8.5) 62.6 (8.9) 59.8 (8.1) 2.25 1 0.14
Sex, male, n 60 27 33 0.39 1 0.60
Cardiovascular characteristics (n)
CAD event 0.74 3 0.86
MI/IHD 29 11 18
PTCA 28 12 16
CABG 20 10 10
Other 2 1 1
Smoking history 2.19 2 0.34
Previous smoker 42 19 23
Current smoker 8 5 3
Hypertension 51 23 28 0.25 1 0.62
Diabetes 19 11 8 2.25 1 0.19
Obese (BMI > 30) 27 11 16 0.09 1 0.81
Dyslipidemia 61 28 33 0.90 1 0.42
Psychometric characteristics
HAM-D17 total score, mean (SD) 7.5 (6.1) 7.3 (6.7) 7.6 (5.6) 0.05 1 0.83
History of depression, n 32 14 18 0.11 1 0.92
Biochemical characteristics
Plasma EPA + DHA (lg/ml), mean (SD) 73.8 (32.0) 64.1 (22.2) 81.3 (36.4) 6.10 1 0.016
Serum LPH (lM), mean (SD) 17.9 (12.6) 17.7 (12.5) 18.2 (12.8) 0.03 1 0.88
Serum 4-HNE (fmol/lg), mean (SD) 45.6 (15.5) 44.5 (16.8) 46.4 (14.7) 0.27 1 0.60
Serum 8-ISO (pg/mL), mean (SD) 0.11 (0.07) 0.11 (0.06) 0.12 (0.08) 1.35 1 0.25
Serum MDA (uM), mean (SD) 0.04 (0.02) 0.04 (0.02) 0.04 (0.02) 0.01 1 0.91
Abbreviations: SD, standard deviation; df, degrees of freedom; n-3 PUFA, omega-3 polyunsaturated fatty acid; MI, myocardial infarction; IHD, ischemic heart disease; PTCA,
percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft; BMI, body mass index; HAM-D, 17-Item Hamilton Depression Rating Scale; EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid; LPH, lipid hydroperoxides; 4-HNE, 4-hydroxy-2-nonenal; 8-ISO, 8-isoprostane; MDA, malondialdehyde.
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samples and were included in the present study.
Patient characteristics are summarized in Table 1. There were
no differences in the history of CAD, cardiovascular risk factors,
history or severity of depression, or concomitant medications used
between the treatment groups. The majority of patients were using
statins (99%), acetylsalicylic acid (86%), and antihypertensives
(75%), whereas few patients were using anti-inflammatory agents
(4%), anxiolytics (6%), or antidepressants (14%). Baseline (prior to
treatment) plasma EPA + DHA concentrations were greater in the
placebo group than in the n-3 PUFA group.3.1. Lipid peroxidation and depressive symptom outcomes
There were no differences in the baseline raw concentrations of
the lipid peroxidation markers between the treatment groups
[Table1]. In the primary analysis, a greater baseline MDA/LPH ratio
was significantly associated with depressive symptom improve-
ment over 12 weeks with n-3 PUFA treatment [Table 2, Fig. 1].
In exploratory analyses, greater baseline ratios of 4-HNE/LPH andTable 2
A greater baseline ratio of late-stage/early-stage lipid peroxidation predicts changes in HA
Outcome F1,33a n-3 PUFA (n = 34)
B (SE)b bb
Unadjusted models
MDA/LPH (primary) 11.93 3.10 (0.99) –0.50
4-HNE/LPH 9.29 3.65 (1.38) –0.44
8-ISO/LPH 8.37 2.65 (1.11) –0.42
Adjusted models
MDA/LPH (primary) 6.20 2.17 (1.04) –0.35
4-HNE/LPH 5.35 2.60 (1.41) –0.32
8-ISO/LPH 6.10 2.07 (1.11) –0.33
Italicized values indicates statistical significance.
a Repeated measures linear regression models were used for the main analysis. The p
b B (SE) and b coefficients from linear regression were included to present the direction
EPA + DHA concentrations as covariates.8-ISO/LPH each significantly predicted greater improvement in
depressive symptoms over 12 weeks of n-3 PUFA treatment
[Table 2, Fig. 1].
These ratios remained significant predictors of improvement
with treatment after adjusting for age and for the baseline plasma
concentration of EPA + DHA [Table 2]. Greater baseline EPA + DHA
concentrations were an independent predictor of improvement
with treatment in each model (MDA/LPH model: F1,33 = 11.05,
p = 0.002; 4-HNE/LPH model: F1,33 = 11.36, p = 0.002; 8-ISO/LPH
model: F1,33 = 13.15, p = 0.001).
Neither the baseline lipid peroxidation ratios [Table 2] nor the
baseline plasma EPA + DHA concentrations were associated with
depressive symptom changes over 12 weeks in the placebo group
in either the unadjusted or adjusted models.3.2. Post-hoc analyses
In the per-protocol subgroup of patients treated with n-3 PUFA
(n = 29), greater baseline ratios of MDA/LPH (adjusted: F1,28 = 5.88,
p = 0.024), 4-HNE/LPH (adjusted: F1,28 = 9.12, p = 0.006), and 8-ISO/M-D total scores with n-3 PUFA treatment, but not with placebo.
F1,44a Placebo (n = 45)
Pa B (SE)b bb Pa
0.001 0.12 0.06 (1.74) –0.01 0.73
0.005 0.46 0.45 (2.09) –0.03 0.50
0.007 2.36 2.15 (1.41) –0.22 0.13
0.018 0.12 0.09 (1.78) 0.01 0.73
0.027 0.40 0.58 (2.13) –0.04 0.53
0.019 2.69 2.41 (1.48) –0.25 0.11
value represents that of the repeated measures regression.
of the observed associations. The adjusted models included age and baseline plasma
Fig. 1. Associations between late-stage/early-stage ratios and change in depressive
symptoms with 12 weeks of n-3 PUFA treatment. All associations were statistically
significant in both unadjusted and adjusted models (refer to Table 2 for summary
statistics). None of the data points in each plot (A, B, or C) were determined to be
outliers (interquartile range method). After removal of two visually extreme points
from the 4-HNE/LPH (B) and 8-ISO/LPH (C) ratio data, relationships between those
baseline ratios and depressive symptom changes were no longer significant (refer to
post-hoc sensitivity analyses).
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tors of improvement in depressive symptoms over 12 weeks.
Similarly, after excluding n-3 PUFA treated patients using
antidepressant maintenance medication throughout the trial
(n = 6, resulting subgroup n = 28), greater baseline ratios of MDA/
LPH (adjusted: F1,27 = 6.12, p = 0.019), 4-HNE/LPH (adjusted:
F1,27 = 7.16, p = 0.013), and 8-ISO/LPH (adjusted: F1,27 = 8.48,
p = 0.007) remained significant predictors of improvement in
depressive symptoms over 12 weeks.Deconstructing the baseline lipid peroxidation ratios revealed
that none of LPH (F1,33 = 2.35, p = 0.13), MDA (F1,33 = 2.26,
p = 0.14), 4-HNE (F1,33 = 1.31, p = 0.26), or 8-ISO (F1,33 = 0.92,
p = 0.34) were independently associated with improvement in
depressive symptoms with n-3PUFA after adjusting for covariates.
Although no statistical outliers were found, visual inspection
suggested that the associations between depressive symptom
changes and the 4-HNE/LPH and 8-ISO/LPH ratios may have been
driven by two data points. After removal of those points in sensi-
tivity analyses, neither association (adjusted models, 4-HNE/LPH:
F1,31 = 0.86, p = 0.36; 8-ISO/LPH: F1,31 = 1.05, p = 0.31) remained
significant. Visual inspection did not suggest removal of any data
points from the MDA/LPH ratio.4. Discussion
Greater baseline ratios of late-stage lipid peroxidation markers
to early-stage lipid peroxidation markers in serum were associated
with a greater improvement of depressive symptoms with
12 weeks of n-3 PUFA treatment. As lipid peroxidation markers
reflect oxidative damage to lipids, this finding suggests that
increased oxidative stress may generally be a pre-treatment pre-
dictor of n-3 PUFA antidepressant efficacy. This interpretation is
supported by the finding that oxidative stress was not associated
with depressive symptom changes in the placebo group.
Though the mechanisms by which n-3 PUFA, particularly EPA
and DHA, which were the active ingredients in the formulation
used in this study, mediate antioxidant effects remain unclear, sev-
eral possibilities have been reviewed (Giordano and Visioli, 2014).
For example, EPA and DHA have been shown to form micelles
which scavenge free radicals, and to reduce hydroxyl radical and
superoxide radical production. EPA and DHA have also been shown
to downregulate the expression of NADPH oxidase, a major con-
tributor to oxidative stress. Beyond oxidative stress, EPA and
DHA are associated with downregulation of redox-sensitive tran-
scription factors such as NF-jB, which increase the synthesis of
pro-inflammatory cytokines associated with depression (Dowlati
et al., 2010; Palanisamy et al., 2015). Consistent with these mech-
anisms, the antioxidant effects of n-3 PUFA have been regularly
demonstrated in clinical samples (Azizi-Soleiman et al., 2013; Lee
et al., 2013; Duffy et al., 2015).
As we postulated, a greater MDA/LPH ratio might indicate a
greater conversion of early-stage lipid peroxidation products such
as LPH to later-stage products such as MDA. This implication is
supported by the relationships between the 4-HNE/LPH and 8-
ISO/LPH ratios and depressive symptom change with n-PUFAs
observed in exploratory analyses. High ratios in certain patients
may indicate a high level of oxidative stress and overwhelmed
antioxidant defenses, which may be amenable to n-3 PUFA treat-
ment. The lack of significant relationships between individual
late-stage or early-stage markers and depressive symptom changes
suggests that the degree of conversion from early-stage to late-
stage lipid peroxidation may be more relevant than the absolute
concentrations of lipid peroxidation markers. It also suggests that
these ratios were not driven by a significant relationship between
LPH, their common denominator, and depressive symptom
changes.
The conditions under which an early-stage marker such as LPH
might transform into a particular late-stage marker such as MDA
rather than another late-stage marker such as 4-HNE, in vivo,
remain unclear. This study included multiple late-stage markers
to evaluate a variety of potential late-stage/early-stage ratios,
which appeared to similarly predict depressive symptom changes
in this study. These findings suggest that the late-stage/early-
stage ratio of lipid peroxidation may be reflected using any of
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our sensitivity analysis indicate that MDA may be more robust
than the others. These findings should be confirmed by future
studies.
Oxidative stress has yet to be reported as a predictor of depres-
sive symptom changes with n-3 PUFA treatment in CAD or other
populations; however, previous studies have implicated inflamma-
tory biomarkers as a predictor of antidepressant treatments. Ele-
vated inflammatory activity, which is closely related to oxidative
stress activity (Maes et al., 2011), has been shown to predict
improvements in depressive symptoms among patients treated
with n-3 PUFA (Rapaport et al., 2016). Inflammation may also dif-
ferentially predict response to selective serotonin reuptake inhibi-
tors and anti-inflammatory therapies. For example: while elevated
baseline concentrations of circulating inflammatory markers such
as C-reactive protein, interleukin-6, and tumor necrosis factor
may not be associated with response to sertraline (Bot et al.,
2011) or may predict non-response to escitalopram (Eller et al.,
2008), they appear to predict the antidepressant efficacy of the
tumor necrosis factor-antagonist infliximab (Raison et al., 2013)
and exercise interventions (Rethorst et al., 2013) in patients with
major depressive disorder, both of which have anti-inflammatory
effects (Swardfager et al., 2012). These findings support the inter-
pretation of the late-stage/early-stage lipid peroxidation ratios as
favourable inflammatory/oxidative stress predictor of improve-
ment in depressive symptoms with n-3 PUFA treatment.
This study also identified that greater baseline plasma concen-
trations of EPA + DHA were a significant predictor of improvement
in depressive symptoms with n-3 PUFA treatment, but not with
placebo. This finding contrasts with the hypothesis that n-3 PUFA
deficits might indicate a state of increased responsiveness to n-3
PUFA treatment (McNamara, 2015). Rather, it is in line with previ-
ous evidence that greater baseline n-3 PUFA concentrations predict
greater n-3 PUFA treatment response (Carney et al., 2016). Plasma
and erythrocyte n-3 PUFA may indicate the level of biological n-3
PUFA reserves available to a patient in the midst of depressive
symptoms, CAD, and the increased oxidative stress associated with
those conditions (Mazereeuw et al., 2015; Negi and Anand, 2010).
Consistent with this, cross-sectional studies have shown inverse
relationships between oxidative stress markers and n-3 PUFA in
those with depression (Bigornia et al., 2016; Baek and Park,
2013). Taken together, our findings suggest that adequate plasma
n-3 PUFA concentrations and high oxidative stress prior to treat-
ment may be favourable predictors of n-3 PUFA treatment benefit.
These findings invite future study along several lines. The utility
of lipid peroxidation ratios may be better appreciated in models
including inflammatory markers previously shown to predict n-3
PUFA antidepressant effects. The mechanisms by which LPH may
convert into MDA, 4-HNE, or 8-ISO may elucidate underlying dis-
ease mechanisms which remain poorly understood. Finally, mea-
surement of lipid peroxidation end-products may add
mechanistic insight into the observed relationships between
oxidative stress and n-3 PUFA in this study.
4.1. Limitations
The small sample size in the n-3 PUFA group limited the analy-
ses to the inclusion of only 2 covariates. A larger sample size would
have permitted the inclusion of other patient characteristics such
as concomitant medications or cardiovascular risk factors. A larger
sample size would have also permitted a well-powered investiga-
tion of a treatment X late-stage/early-stage ratio interaction incor-
porating both the n-3 PUFA and placebo groups in the same model.
While there was an imbalance in the number of patients between
the n-3 PUFA and placebo groups, the placebo group was used only
as a comparison for the positive findings observed in the n-3 PUFAgroup. The similarities of patient characteristics in the n-3 PUFA
and placebo groups suggest that patient factors were unlikely to
be responsible for the different findings between them.
Plasma measurements of EPA and DHA have been shown to be
more variable than measurements from erythrocytes (Harris and
Thomas, 2010) and may reflect more recent EPA and DHA intake.
The associations between baseline EPA + DHA concentrations and
depressive symptom improvement with n-3 PUFA should be inter-
preted with this in mind. However, these associations are consis-
tent with those recently observed using erythrocyte
measurements (Carney et al., 2016).
As established normal ranges for serum concentrations of LPH
and other markers have yet to be established, we could not deter-
mine whether the high concentrations measured in this study were
truly high and whether the low concentrations were truly low in
the broader population of persons with CAD. This limited the inter-
pretation of the early-stage and late-stage markers individually
and encouraged the use of the late-stage/early-stage ratios as the
treatment predictors.
Finally, these findings are limited to the CAD population and
may not be generalizable to other populations with depression.
Depressive symptom severity in this sample was mild and uncom-
plicated by psychiatric-comorbidities. Whether the late-stage/
early-stage ratios pertain to n-3 PUFA treatment success in more
severely depressed samples should be investigated in future
studies.
5. Conclusions
Greater oxidative stress prior to n-3 PUFA antidepressant treat-
ment was associated with greater depressive symptom improve-
ment over 12 weeks. These findings support oxidative stress as a
potential biomarker that may clarify the variability in n-3 PUFA
antidepressant efficacy observed in previous trials.
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